Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Erich Fisher, M.D., Ph.D.


This page shows the publications co-authored by David Fisher and Frank Hodi.
Connection Strength

  1. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
    View in: PubMed
    Score: 0.561
  2. Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. Nat Clin Pract Oncol. 2008 Dec; 5(12):696-7.
    View in: PubMed
    Score: 0.406
  3. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008 Apr 20; 26(12):2046-51.
    View in: PubMed
    Score: 0.392
  4. Author Correction: From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2020 Dec; 20(12):757.
    View in: PubMed
    Score: 0.235
  5. A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. Cancer Med. 2016 11; 5(11):3041-3050.
    View in: PubMed
    Score: 0.177
  6. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2012 Apr 05; 12(5):349-61.
    View in: PubMed
    Score: 0.129
  7. Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. Pigment Cell Melanoma Res. 2010 Feb; 23(1):14-26.
    View in: PubMed
    Score: 0.110
  8. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res. 2008 Dec 01; 14(23):7726-32.
    View in: PubMed
    Score: 0.102
  9. Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clin Cancer Res. 2015 Jul 15; 21(14):3178-86.
    View in: PubMed
    Score: 0.040
  10. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul; 2(7):643-54.
    View in: PubMed
    Score: 0.037
  11. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 01; 19(5):1225-31.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.